Tonix Pharmaceuticals

$0.5839
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0386 (-6.20%) As of 11:16 AM EDT today

Why Robinhood?

You can buy or sell TNXP and other stocks, options, and ETFs commission-free!

About TNXP

Tonix Pharmaceuticals Holding Corp. Common Stock, also called Tonix Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY. The listed name for TNXP is Tonix Pharmaceuticals Holding Corp. Common Stock.

CEO
Seth Lederman
Employees
16
Headquarters
Chatham, New Jersey
Founded
2007
Market Cap
75.57M
Price-Earnings Ratio
Dividend Yield
Average Volume
4.33M
High Today
$0.6059
Low Today
$0.58
Open Price
$0.60
Volume
1.89M
52 Week High
$3.99
52 Week Low
$0.3902

Collections

TNXP Earnings

-$5.69
-$3.79
-$1.90
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 6, Pre-Market

You May Also Like